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ABSTRACT
Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients with MM develop
dialysis-dependent acute kidney injury related to increased free light chain (FLC) production by a plasma cell clone.
Myeloma cast nephropathy (MCN) is the most prevalent pathologic diagnosis associated with renal injury, followed by light
chain deposition disease and light chain amyloidosis. Several FLC removal techniques have been explored to improve
kidney disease in MM but their impact on renal clinical outcomes remains unclear. According to the evidence, high cut-off
haemodialysis should be restricted to MM patients on chemotherapy with histological diagnosis of MCN and haemodialysis
requirements. From our perspective, more efforts are needed to improve kidney outcomes in patients with MM and renal
failure.
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INTRODUCTION
Multiple myeloma (MM) is the result of a proliferation of a neo-
plastic clone of plasma cells in the bone marrow and encom-
passes 13% of all haematologic malignancies [1], showing an
annual incidence of 60 cases per million population [2].
Clinical manifestations are heterogeneous, ranging from skele-
tal disease (70%), anaemia (40%), impaired humoural immunity
(80%) and, as we will focus on this review, renal impairment
(20–40%) [3, 4].
Since late last century, when immunofluorescence and elec-
tronic microscopy clarified the physiopathology of myeloma
kidney, several therapeutic strategies have been tested to re-
duce the impact of myeloma paraproteins on kidney function,
especially with extracorporeal techniques to remove free light
chains (FLCs) [e.g. plasmapheresis (PLEX) or high cut-off (HCO)
dialysis]. There were also some efforts to characterize FLCs’
structure and physico-chemical properties in order to investi-
gate potential inhibitors of FLCs’ intratubular aggregation.
Herein, our purpose is to review all the relatively new thera-
peutic strategies from a nephrologist’s perspective, focusing on
the use of extracorporeal techniques to reduce the levels of
FLCs in serum, especially with HCO dialysis membranes. We
also summarize the knowledge acquired over the last two deca-
des regarding the implication of FLCs in the renal pathology of
MM.
PATHOGENESIS: THE ROLE OF FLCs
The first documentation of the existence of FLCs dates from
1845 [5], when a 38-year-old greengrocer from London devel-
oped bone pains and generalized swelling. His physician
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noticed a unique protein in his urine and sent a sample to
Henry Bence Jones, the chemical pathologist from whom these
proteins would take their name. More than a century later, in
1963, Edelman would characterize these molecules as FLCs [6].
Under normal conditions, plasma cells synthesize 40% more
light than heavy chains [7], and this excess of FLCs is thought to
favour accurate assembly of intact immunoglobulins. As a re-
sult, 500 mg of polyclonal FLCs are given to blood circulation
every day [7, 8]. In humans, light chains are encoded by two dif-
ferent gene loci, resulting in the serologically distinguishable
light chain types, lambda and kappa. While the former is a
22.5 kDa monomer, the latter tend to be a dimeric protein of
45 kDa. The small molecular weight confers FLCs a high distri-
bution volume, so intravascular space contains only 15–20% of
them.
FLCs filtrate through glomerular endothelium and basal
membrane, reaching the proximal tubule, where they are endo-
cyted by the megalin–cubilin complex and then degraded into
their constituent amino acids inside tubular cells.
In the setting of a plasma cell dyscrasia, FLC production
increases regardless of what type of immunoglobulin is produced.
In fact, 80% of all MM patients produce monoclonal intact immu-
noglobulins, with 95% of these also producing monoclonal serum
FLCs [9]. Although heavy chains and intact immunoglobulins re-
main in blood circulation, FLCs go through the glomerular filtration
barrier to proximal tubule lumen and exceed the capacity of
absorption-catabolism of tubular epithelial cells. As a consequence,
these molecules are easily detected in urine.
RENAL LESIONS IN MM: SOME
CONSIDERATIONS
When FLC production is increased, FLCs can be isolated from
urine (Bence Jones protein) but they can also remain in distal tu-
bular structures, forming crystalline aggregates with the
Tamm–Horsfall glycoprotein (THP) or uromodulin, appearing as
eosinophilic casts under light microscopy examination; the so-
called myeloma cast nephropathy (MCN) (Figure 1A). In MCN,
there is proteinuria without albuminuria, since the glomerular
basement membrane remains undamaged.
On the contrary, FLCs can deposit on the glomerular base-
ment membrane and mesangium as well, producing disruption
of the filtration barrier (Figure 1B and C). If FLCs are disposed as
beta-shaped arranged fibrils interacting with serum amyloid P,
they will cause light chain amyloidosis (AL), whereas if FLCs are
deposited themselves without any organization they will pro-
duce light chain deposit disease (LCDD). In both pathologic enti-
ties, there is albuminuria because there is glomerular filtration
barrier damage. AL is usually presented as nephrotic syndrome,
often without renal dysfunction, whereas LCDD displays renal
dysfunction, microhaematuria and albuminuria [10].
Therefore, FLCs cause different types of kidney injury in MM
depending on which histological compartment is affected. The
presence and type of proteinuria (Bence Jones proteinuria or al-
buminuria) remains the cornerstone for the clinical approach to
characterize the kidney injury in MM (Figure 2).
Nasr et al. [10] retrospectively reported renal pathology find-
ings of 190 MM patients. Kidney biopsies were obtained as part
of the standard clinical practice, and main indications were
acute kidney injury (AKI) (55%), progressive renal failure with
proteinuria (27%), proteinuria without decrease in glomerular
filtration rate (9%) and nephrotic syndrome (14%). To be in-
cluded in the study, the diagnosis of MM must have been made
before kidney biopsy or shortly thereafter. They found that the
most common renal lesion (33%) was MCN, followed by LCDD
(22%) and AL (21%). Remarkably, 23% of the pathologic diagnos-
tics were not clearly caused by the paraprotein.
They reported a 9% incidence of acute tubular necrosis, iden-
tifying at least one precipitating factor in 60% of cases: non-
steroidal anti-inflammatory drugs use (40%), dehydration (30%),
hypercalcaemia (30%), zoledronate (30%) and intravenous iodin-
ated contrast (10%). Nephroangiosclerosis (6%) or diabetic ne-
phropathy (5%) followed as the most common non-paraprotein-
associated lesions.
This observation highlights the importance of the renal bi-
opsy to perform a correct diagnosis and makes clear that kidney
dysfunction in MM is not always related to it. This concept is
crucial to the interpretation of the results raised by interven-
tional studies, as theoretically the extracorporeal clearance of
FLCs is only effective when there is paraprotein-mediated kid-
ney injury. In the Nasr et al. study [10], MCN was the lesion with
the highest dialysis requirements (37%). Moreover, in other
studies focusing on patients with AKI, the prevalence of MCN
rose to 66–87% [11, 12].
KIDNEY INJURY AS A PROGNOSTIC FACTOR
IN MM
Focusing on AKI and dialysis needs, Haynes et al. [12] studied the
clinical outcomes of 107 MM patients with AKI. They found three
FIGURE 1: Clinicopathologic renal lesions in MM. (A) Eosinophilic intratubular casts in MCN (haematoxylin and eosin stain); (B) tubular and glomerular basement mem-
ebranes stained by anti-lambda antibodies in LCDD (immunofluorescence microscopy); (C) orange stain of mesangium and arteriole corresponding to AL fibril deposits
(Congo red stain).
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main protective factors: use of chemotherapy, serum albumin
>35 g/L and dialysis independence. There were 88 patients re-
quiring haemodialysis (HD), and only 15 of them (17%) reached
dialysis independence during the follow-up, although the so-
called ‘novel therapies’ (bortezomib and lenalidomide) were not
used in this study. Dialysis independence is higher in more re-
cent studies using these new chemotherapy agents, ranging from
21% to 50% [13–16]. Although these studies are small, it seems
that renal injury reversibility could be increased by using novel
therapies. However, even with these new therapies, kidney func-
tion recovery rates still remain low (<50%).
EXTRACORPOREAL TECHNIQUES: PLEX
The half-life of circulating FLCs is 3–6 h in normal renal function
[17] but it shows an inverse correlation with glomerular filtra-
tion rate, as the kidney is the main FLC catabolism site. Thus,
FLC half-life increases to 10-fold in patients with CKD stage 5
[18]. As such, in AKI secondary to MCN, the functioning neph-
rons would be overexposed to FLCs for a significant period of
time, even after successful chemotherapy. Removing FLCs in
this situation will cease the ‘vicious circle’, accelerating the FLC
decrement by an artificial ‘catabolism’, and therefore reducing
the FLC burden in the non-injured nephrons that would other-
wise collapse (Figure 2).
Plasma exchange or PLEX was the only extracorporeal
technique to remove circulating FLCs until 2005, when the
HCO-HD membranes appeared. Since then, several studies
have been conducted to evaluate its efficacy. Nevertheless,
there are only three published randomized and controlled
clinical trials [19–21] (Table 1), and all of them failed to dem-
onstrate a therapeutic effect of PLEX on MM renal dysfunc-
tion. However, all studies show limitations in terms of
drawing robust conclusions. Although there is a lack of sta-
tistical power in the first two studies [19, 20], the most re-
cent, conducted by Clark et al. [21], does not report the renal
histology and FLC monitoring, making it very difficult to as-
certain whether the study groups were comparable regarding
the type and severity of renal disease. The inconclusive
results led to PLEX being downgraded from Category II to a
Category III indication in MM with AKI by the American
Society for Apheresis [22] in 2007.
In 2008, Leung et al. [23] published a retrospective study on
PLEX considering renal biopsy findings and FLC reduction. Forty
patients were treated with PLEX (an average of six sessions) and
85% received chemotherapy as well. In MCN, the renal response
greatly depended on the attained FLC reduction, being signifi-
cantly higher in those patients achieving circulating FLC reduc-
tion >50%. Remarkably, these results were not observed in
patients without MCN. This study clearly illustrates the impor-
tance of the histological diagnosis and the relationship between
FLC reduction and clinical outcomes in MCN, endorsing thera-
peutic schemes based on FLC levels instead of pre-fixed or arbi-
trary protocols. Further and well-designed clinical trials are
needed to definitively refuse or accept the utility of PLEX as an
adjuvant therapy.
FIGURE 2: Mechanisms of FLC-induced nephropathy and its clinical correlation. In the upper right corner, we show the theoretical advantage of using extracorporeal
techniques for FLC removal.











In 2005, a new generation of HD membranes known as ‘protein
leaking membranes’ were designed as an alternative way to pro-
vide greater clearances of high molecular weight substances in-
volved in uraemia, which are not removed by high flux
membranes [24]. The so-called ‘high cut-off membranes’ owed
their name to their wide pore size, which enhanced the molecular
weight cut-off to 50–60 kDa [25]. By using these HCO membranes,
the extracorporeal treatments could be more intensive and longer-
lasting than those by PLEX, thus reducing the FLC rebound and
preventing PLEX complications such as clotting or severe hypopro-
teinaemia. However, it has to be noted that albumin (68 kDa) leaks
across those HCO membranes, which is their main limitation.
The most relevant studies on FLC removal by using HCO fil-
ters were published in 2007 [26] and 2008 [27], both led by Dr
Hutchison. These articles established some core concepts in
terms of dialysis characteristics (clearance, time, convection use,
albumin leakage and membrane surface) to establish rational
therapeutic schemes to evaluate the effects of FLC reduction on
clinical outcomes. One of the most relevant conclusions reached
in these studies [26, 27] is that HCO-HD could be useful in acceler-
ating the decrease of serum FLCs provided by effective
chemotherapy. Therefore, without a concomitant decrease in the
FLC production rate, extracorporeal depuration will only generate
a transient decrease of FLCs followed by a ‘rebound’ thereafter.
Accordingly, 19 patients with MM, AKI HD-dependent and
diagnosis of MCN by renal histology were initially included in
a study to receive standard chemotherapy regimen and HCO-
HD [28]. Six patients had their chemotherapy interrupted be-
cause of complications and they displayed a moderate FLC
reduction, <40%. In contrast, patients combining chemother-
apy and HCO-HD showed an 85% decline in the FLC levels
and, more importantly, all achieved the renal recovery end-
point, defined as dialysis independence 2 weeks after last di-
alysis session. Although cautious, the observed 100% recov-
ery rate (13/13) is promising, particularly when compared
with recovery rates (20%) reported in previous studies
[12, 13]. Nonetheless, it seems reasonable to conclude that,
independently of whether HCO-HD is useful or not, its use
should be limited to patients eligible for receiving an effec-
tive chemotherapeutic treatment.
Two successive studies [29, 30] examined if early reductions
in serum FLCs were associated with better outcomes and if
there was a specific FLC reduction threshold to achieve the re-
nal improvement. In both series of patients (39 and 67, respec-
tively) renal recovery rate was 60%. The authors found that FLC
reduction on Day 21 was associated with renal recovery. Also,
Table 1. Randomized and controlled trials evaluating the efficacy of plasma exchange in MM-associated AKI
Zucchelli et al. [19] Johnson et al. [20] Clark et al. [21]
Year 1988 1990 2005
Number of patients 29 21 97
Study population • AKI (Cr >5 mg/dL with previous nor-
mal determination)
• MM diagnosis
• AKI (Cr >270 lmol/L with previous nor-
mal determination)
• MM diagnosis
• AKI (Cr >200 lmol/L with an in-
crease >50 lmol/L in preceding 2
weeks)
• MM diagnosis
Intervention Corticosteroids þ cyclophosphamide
in both groups:
• PLEX (n¼15): plasma exchange 5 ses-
sions 5 consecutive
days (3–4 L plasma each session).
HD when required
• No PLEX (n¼14): no plasma ex-
change. Peritoneal dialysis
when required
Prednisone þmelphalan in both groups:
• PLEX (n¼11): plasma exchange thrice a
week for 1–4 weeks (7.9 6 3.3 sessions
of average volume exchanged of 3495
mL)
• No PLEX (n¼10): conservative
management
Melphalan þ prednisone or vin-
cristine-adriamycin-
dexamethasone:
• PLEX (n¼58): 5–7 plasma ex-
change of 50 mL/kg within the
first 10 days of study entry
• No PLEX (n¼39): conservative
management
Dialysis need 24/ 29 (13 HD; 11 peritoneal dialysis) 12/21 (PLEX:5 ; No PLEX:7) 29/97 (PLEX 15; control 14)
Outcomes • Dialysis independence
No PLEX: 2/11
• Dialysis independence PLEX: 11/13
(P<0.01)
• Dialysis independence No PLEX : 0/5
• Dialysis independence PLEX: 3/7
(P ¼ NS)
• Composite outcome of death, di-
alysis dependence or GFR
< 30 mL/min without statistical
difference
• Dialysis Dependence No PLEX:
26.9%
• Dialysis dependence PLEX: 12.8%
(P¼0.2)
Biopsies 17 biopsies performed (16 MCN; 1
proximal tubular affection)





Not available Not available Not performed
Commentaries • No PLEX Group showed high mortal-
ity rates, making questioned its
results (small cohort, high type 1
error)
• Not all patients biopsied, nor FLC
determination performed
• Not all patients biopsied, nor FLC deter-
mination performed
• The only predictor of renal recovery
was the number of cast per biopsy
(P¼0.027)
• Large study, no differences
proved, but lacking of histologi-
cal diagnosis and FLC
monitoring
GFR, glomerular filtration rate; NS, non-significant.
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although they did not find a clear threshold, there was a linear
relationship between the FLC reduction and the probability of
renal recovery, as 60% FLC reduction was associated with 80%
dialysis independence. This correlation was presumed in previ-
ous works [23], suggesting that there could be some biochemical
targets in order to improve renal outcomes and, consequently,
survival rates in MM patients.
Finally, two randomized clinical trials were conducted to
prove the efficacy of HCO-HD as an adjuvant therapy for HD-
dependent AKI in MM patients receiving concomitant che-
motherapy (Table 2). One of them, the European trial of free
light chain removal by extended haemodialysis in cast ne-
phropathy (EuLITE) trial [31], has not yet been published, but
preliminary results were given in abstract form. Meanwhile,
the MYRE trial [32], has recently been published. There are
some considerations to be taken into account when inter-
preting the results reported in said trials. In the EuLITE trial,
the proportion of patients in which chemotherapy was dis-
continued was not reported. On the other hand, there was a
higher proportion of patients having severe infectious
complications in the experimental group, raising some con-
cerns on group differences regarding immunoparesis, MM se-
verity or antibiotic-dose adjustment. Finally, the use of two
filters in series could provide higher FLC clearance, but im-
plied higher risk of hypoalbuminaemia and its related com-
plications. When published, the definitive results may
enable us to undertake a thorough analysis of this work. In
the MYRE trial [32] the primary end point consisting of HD in-
dependence at 3 months was not achieved, although renal
recovery at 6 and 12 months was higher in the HCO-HD arm.
The study was underpowered to identify early clinically rele-
vant differences while there was no clear hypothesis for the
observed delayed therapeutic effect. In fact, as previously de-
scribed [29], FLC decrease at Day 21 should be a predictor of
renal recovery with a median time of dialysis independence
of 27 days (ranging from 7 to 107 days).
In conclusion, we currently know that HCO membranes en-
hance FLC clearance in HD-dependent AKI secondary to MCN.
The advantage of HCO-HD use upon standard of care is still con-
troversial; definitive results of some studies and more
Table 2. Randomized and controlled trials evaluating the efficacy of HCO-HD in MCN
EuLITE [31] (2008–15; not published) MYRE [32] (2011–16)
Patient number 90 98 randomized
94 analysed
Study population Newly diagnosed myeloma
MCN confirmed by biopsy
Clinical indication HD
Allocation within 10 days from diagnosis
New or untreated myeloma
MCN confirmed by biopsy
Clinical indication HD
4- to 15-day screening period (conservative management)
Calculation sample size Assuming 25% recovery rates in controls
55% in treatment group
Assuming 30% recovery rates in controls
60% in treatment group
Analysis Intention to treat Intention to treat
Treatment Bortezomib (1 mg/m2 Days 1, 4, 8, 11, 21)
Doxorubicin
Dexamethasone
Bortezomib (1.3 mg/m2 Days 1, 4, 8, 11)
Dexamethasone
Cyclophosphamide (750 mg/m2 after 3rd cycle, if NO
response)
HD protocol Two 1.1 m2 filter in series (Gambro HCO1100)
6 h Day 0
8 h Days 2, 3, 5, 6, 7, 9, 10
From 12 day: 8 h alternate days
After 21 day: 6 h alternate days
*Replacement with 60 g albumin solution each
session
Single 2.1 m2 dialyser (Theralite, Gambro)
5 h/session
8 sessions first 10 days
Thereafter: 3 sessions weekly if needed, until completion 3
chemotherapy cycles)
*If <25 g/L serum albumin prior HD, post-dialysis perfusion
of 20 g albumin
End points; results Primary endpoint:
HD independence at 3 months: 55.8% in HCO group
versus 51.6% in control; P ¼ NS
Primary endpoint:
HD independence at 3 months: 41.3% treatment versus
33.3% control; P ¼ 0.42
Secondary endpoints:
HD independence at 6 months: 56.6% treatment versus
35.4% control; P ¼ 0.04
HD independence at 12 months: 60.9% treatment versus
37.5% control; P ¼ 0.02
Hematologic response at 3 monthsa: 89.1% treatment ver-
sus 62.5% control; P ¼ 0.03
Haematologic response at 6 monthsa: 78.3% treatment ver-
sus 60.4% control; P¼ 0.06
Other relevant data Number infections treatment group: 13
Number infections control group: 2 (P ¼ 0.014)
Variables associated significatively with favourable kidney
outcome within 12 months (multivariate analysis):
- Whole immunoglobulin MM: OR 2.75
- Level FLC after first cycle <500mg/L: OR 2.51
- Use of HCO-HD: OR 2.78
aHaematologic response overall: it includes partial (decrease of >50% FLC), very good partial (>90%) or complete response (normal level or ratio).
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Randomized Controlled trial are needed. However, it must be
noted that the International Myeloma Working Group (IMWG),
in their 2016 recommendations on myeloma-related renal im-
pairment, has already stated that the current data supports the
use of HCO-HD in AKI HD-dependent secondary to MCN with an
evidence grade B [33].
LOOKING FOR PROGNOSIS FACTORS: TIME,
BIOPSY OR BOTH?
As the pathogenic role of FLCs on intratubular cast formation is
accepted, we can hypothesize that there is some relationship be-
tween the duration of FLC exposure and the irreversibility of re-
nal injury. Hutchinson et al. [30], found a more favourable
prognosis in patients who initiated the HCO-HD technique within
7 days of presentation compared with those who initiated it later.
This is the only available information we already have in terms
of HCO-HD therapy delay, but it seems reasonable considering
that immediate decrease of FLCs could entail less renal injury.
However, in real life, usually it is not possible to determine
for how long the kidneys have been injured by circulating FLCs.
There is no data about the natural history of MCN or subclinical
effects of FLCs on renal structures, because histological diagno-
sis is only considered when there is AKI, so the outcomes might
be different depending on the acute/chronic lesion burden in
the kidney (as it is described in other glomerular or tubular enti-
ties). Therefore, the renal biopsy could help to clarify which
patients are more likely to respond when chronologic diagnosis
is unknown.
Although the information regarding the prognostic value of
kidney biopsy is scarce, some studies attempted to relate histo-
logical lesions with clinical prognosis. In Johnson’s study [20],
for example, low cast burden in biopsy (<5/specimen) was sig-
nificantly related to better renal prognosis. Summarized in
Table 3 are the most relevant studies in terms of clinical and
pathologic relationships [4, 34, 35]. Overall, cast burden and tu-
bular atrophy seem the best predictors for worse renal out-
comes in MCN. However, as previously pointed out, renal injury
in MM could be caused by other entities (MM-related and non-
related), so the histological confirmation of MCN is recom-
mended before initiating HCO-HD. Beyond identifying MCN, the
kidney biopsy could become a tool to predict which patients are
Table 3. Main studies evaluating histological prognosis predictors in MCN biopsies
Rota et al. [4] Ecotière et al. [34] Basnayake et al. [35]
Number of patients 34 (26 MCN) 70 4
Population • AKI (Cr >300 lmol/L)
• MM diagnosis
• AKIN Stage 3
• MM diagnosis (IMWG)
• AKI HD dependent
• MM diagnosis
• Treatment with chemotherapy þ
HCO-HD for 6 weeks without renal
response
Clinical outcomes • Group 1: recovered renal
function
• Group 2: partial recovered renal
function
• Group 3: non-recovered renal
function
• Renal response: eGFR >30 mL/min or
HD independence at 3 months
• Haematological response according to
IMWG criteria
• Time to independence from dialysis
after 6 weeks control biopsy
Follow-up No specified Median 17.5 months (1–146) No specified




• Number of cast
• Tubular atrophy





• Index of chronic damage (%)
• Number of tubules with cast (%)
• Interstitial infiltrate (heavy, moder-
ate or light)
Results Tubular atrophy (P¼0.05) between
recovered and non-recovered re-
nal function
Whole study population:
• Median number of cast between renal
responders and non-responders (14 ver-
sus 25; P¼0.004)
Haematological responders subgroup:
• Median number of cast between renal
responders and non-responders (13 ver-
sus 30; P¼0.004)
• Extent tubular atrophy between renal
responders and non-responders (54 ver-
sus 92%; P¼0.031)
Reduction in percentage of cast bur-
den of 31.8% ; 27.3%; and 13.6% were
showed in three of the patients who
recovered. Reduction of 0.6% was
noted in non-recovered patient
* Not statistically significant
Commentaries/
other information
• Number of casts was not signifi-
cant (but 15 samples were exclu-
sively cortical); it could be a
limitation
• Recovery times were median 77
days in Group 1 and 145 days in
Group 2
• FLC reduction at Day 21 was higher in
renal responders (92% versus 24, 4%;
P¼0.005)
• Cast number per 10 fields did not corre-
late with FLC level (Spearman ¼ 0.30)
• Despite significant reductions of FLC
equally distributed in all four
patients (63.9–92.9%), one of them
did not show improvement in cast
burden
eGFR, estimated glomerular filtration rate.
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more likely to respond with intensive HCO-HD treatment. Even
a ‘control’ biopsy could guide us in maintaining the therapy in
patients likely to achieve delayed recovery of renal function. All
of these concepts must be proven and properly explored in
further studies, with the aim of stratifying which patients are
more likely to respond. Perhaps the question is not whether
HCO-HD works or not, but in which kind of patients it could
have the most positive impact.
FIGURE 3: Proposed algorithm for AKI management and use of HCO-HD in MM patients. Clinical criteria for using HCO in bold, according to available evidence; all of
them should be met simultaneously before initiating HCO-HD. FLC monitoring is recommended when using HCO-HD to assess the technique efficacy and be aware of
biochemical outcomes related with favourable prognosis. IFE, immunofixation electrophoresis; SPE, serum protein electrophoresis.











While kappa chains tend to be more common in MCN and
LCDD, lambda chains are more amyloidogenic [10]. However, as
previously anticipated, each light chain type shows a different
‘nephritogenicity’, beyond kappa or lambda classification. In
fact, the severity of renal injury is not always directly related to
FLC levels in plasma or urine [36, 37]. One of the major reasons
for such inconsistency, beyond some well-known precipitating
factors such as dehydration, is the affinity of the FLC variable
domain with the THP, which is a constitutive protein synthe-
tized and secreted into the tubular lumen by tubular cells. This
protein was isolated from the cast of MCN kidneys for the first
time in 1990 [38] by Paul Sanders and represented a milestone
in terms of knowledge on this illness. Over the following two
decades, Sanders studied the interaction between FLC and THP
and introduced the basis for new therapy strategies [39, 40, 41].
Each light chain contains two globular subunits, termed vari-
able (VL) and constant (CL) domains. Three hypervariable seg-
ments of VL [complement determining regions (CDRs): CDR1,
CDR2 and CDR3] produce loop structures conforming to a hydro-
phobic interior that interact with antigens [42]. In 2001, Ying
and Sanders [39] identified the CDR3 region as a single binding
site of light chains for THP, and the different affinity of several
FLCs for THP was also proved. In 2012 [40] they published a rele-
vant study that was focused on synthesizing a competitive in-
hibitor peptide. Firstly, they used information from previous
affinity data of different CDR3 domains and synthesized a pep-
tide based on CDR3 peptide sequences known to interact
strongly with THP. The final inhibitor peptide was examined by
a competitive Enzyme-Linked Immunosorbent Assay and was
proved to show intensive inhibitory activity of human FLC-THP
binding. In the second part of the study, this inhibitor was
tested in vivo in a rodent model of AKI MCN, induced by intra-
peritoneal administration of FLCs. The authors compared the
efficacy of injecting the competitor peptide intraperitoneally or
vehicle alone 2 h before FLC injection. Interestingly, there was
less cast burden and lower serum creatinine (Cr) in the treated
rats. Despite these promising results, further studies are
warranted.
CONCLUSIONS
Efficacy on FLC reduction by HCO-HD filters has been demon-
strated, but its impact on renal clinical outcomes remains
unclear. According to the evidence, HCO-HD use should be re-
stricted to MM patients on chemotherapy with histological diag-
nosis of MCN and HD requirements (Figure 3). The next step
should be to identify which patients could benefit the most. It
seems that some factors could influence the outcomes of these
therapies (time of initiation, type and chronicity of renal
lesions, lambda or kappa FLCs, drug adjustments and duration
of treatment). Certainly, the information provided by the kidney
biopsy is relevant for guiding treatment in cases with severe re-
nal involvement. From our perspective, more efforts are needed
to improve kidney outcomes in patients with MM and renal
injury.
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